130 related articles for article (PubMed ID: 35217151)
1. Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies.
Iyer PG; Codipilly DC; Chandar AK; Agarwal S; Wang KK; Leggett CL; Latuche LR; Schulte PJ
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2772-2779.e8. PubMed ID: 35217151
[TBL] [Abstract][Full Text] [Related]
2. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.
Khoshiwal AM; Frei NF; Pouw RE; ; Smolko C; Arora M; Siegel JJ; Duits LC; Critchley-Thorne RJ; Bergman JJGHM
Gastroenterology; 2023 Nov; 165(5):1168-1179.e6. PubMed ID: 37657759
[TBL] [Abstract][Full Text] [Related]
3. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
4. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
[TBL] [Abstract][Full Text] [Related]
5. A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum JR; Duits LC; Khoshiwal AM; Bergman JJ; Falk GW; Diehl DL; Khara HS; Smolko C; Arora M; Siegel JJ; Critchley-Thorne RJ; Thota PN
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00631. PubMed ID: 37622544
[TBL] [Abstract][Full Text] [Related]
6. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
7. Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia.
Frei NF; Khoshiwal AM; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Ten Kate FJW; Seldenrijk KA; Meijer SL; Critchley-Thorne RJ; Bergman JJGHM
Am J Gastroenterol; 2021 Apr; 116(4):675-682. PubMed ID: 33982936
[TBL] [Abstract][Full Text] [Related]
8. TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus.
Diehl DL; Khara HS; Akhtar N; Critchley-Thorne RJ
Endosc Int Open; 2021 Mar; 9(3):E348-E355. PubMed ID: 33655033
[No Abstract] [Full Text] [Related]
9. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology.
van der Wel MJ; Coleman HG; Bergman JJGHM; Jansen M; Meijer SL;
Gut; 2020 May; 69(5):811-822. PubMed ID: 31852770
[TBL] [Abstract][Full Text] [Related]
10. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
11. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
12. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
13. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
[TBL] [Abstract][Full Text] [Related]
14. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
15. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
16. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
17. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
18. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
Sato F; Jin Z; Schulmann K; Wang J; Greenwald BD; Ito T; Kan T; Hamilton JP; Yang J; Paun B; David S; Olaru A; Cheng Y; Mori Y; Abraham JM; Yfantis HG; Wu TT; Fredericksen MB; Wang KK; Canto M; Romero Y; Feng Z; Meltzer SJ
PLoS One; 2008 Apr; 3(4):e1890. PubMed ID: 18382671
[TBL] [Abstract][Full Text] [Related]
19. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
20. Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score).
Brown CS; Lapin B; Goldstein JL; Linn JG; Talamonti MS; Carbray J; Ujiki MB
Ann Surg; 2018 Apr; 267(4):716-720. PubMed ID: 28230661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
